Aug 25, 2021
Prior to the COVID-19 (SARS-CoV2) pandemic, vaping-related illness was the prevailing public health concern. The incidence of vaping related illnesses mainly e-cigarette, or vaping, product use–associated lung injury (EVALI) declined with the arrival of COVID 19 but EVALI should still be considered as a differential diagnosis for people with COVID-19 for reasons outlined in this review.
This narrative review describes vaping devices, summarizes the adverse health effects of vaping on the lungs and other systems, considers the potential interplay between vaping and COVID-19, and highlights gaps in knowledge about vaping that warrant further research.
